Abstract
The downstream process development for biopharmaceuticals is faced with increasing challenges. A growing market of drug candidates and new molecule families, as well as a rising trend to personalized medicine lead to an increase in market diversity. At the same time more purification techniques and materials become available, resulting in an exponential growth in potential parameter combinations and conditions to be considered and screened for. The establishment of high throughput screening (HTS) technologies and automated liquid handling stations (LHS) have driven standardization in experiments, data handling and data quality assessment in the last decade. Despite, the establishment of automation technologies for almost all purification process steps throughout the field of DSP development, a miniaturization beyond the scale of 96-well plates has not been reached, as sample handling and pipetting accuracy fell short with established LHS...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
